BD, Accelerate Diagnostics partner on rapid antibiotic testing

BD (NYSE:BDX) announced that it entered into a worldwide commercial collaboration agreement with Accelerate Diagnostics (Nasdaq:AXDX).

Under the agreement announced earlier this week, BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility, with results offered in hours compared to between one and two days with some traditional laboratory methods.

Anti-biotic-resistant infections have been on the rise for years. In 2016, details released from the 2014 Review on Antimicrobial Resistance (AMR), commissioned by the UK government to address the concern that superbugs, resistant to current antibiotics, could eventually evolve to the point that the drugs are no longer effective.

In 2020, more than 20 biopharmaceutical companies around the world pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund.

Under the agreement between BD and Accelerate, BD will market the Accelerate Pheno …

Read more
  • 0

Accelerate Diagnostics gains EUA for rapid coronavirus antibody test

Accelerate Diagnostics (NSDQ:AXDX) and BioCheck announced that they received FDA emergency use authorization for their COVID-19 antibody test.

The BioCheck SARS-CoV-2 IgM and IgG combo test and fully-automated MS-Fast instrument that received authorization can process human serum samples in 30 minutes to detect antibodies that indicate recent or prior COVID-19 infection, according to a news release.

BioCheck’s test targets the S1 protein, the major antigen of the novel coronavirus and the protein that the company believes allows for lower probability of false positives due to its lack of similarities to other coronaviruses. According to the companies, other tests that received EUA target the nucleocapsid protein, but they believe the S1 antibodies are more likely to protect against infection.

Accelerate Diagnostics will market, commercialize and support BioCheck’s serology-based testing platform through a previously announced commercial suppl…

Read more
  • 0